Guardant Health (GH) Company Overview

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a top company in precision oncology, announced that on February 6, 2025, it made private exchange agreements with some holders of its 0% Convertible Senior Notes due 2027. As part of this deal, the company will issue $600 million in total principal of 1.25% Convertible Senior Notes due 2031 in return for the existing notes.

This is a comparison of how Guardant Health (GH) and Alnylam Pharmaceuticals (ALNY) have done in relation to their industry this year.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a top company in precision oncology, has announced that it will present data with its research partners at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco from January 23-25, 2025. The presentation will highlight the advantages of Guardant's precision oncology tools in areas such as cancer screening, monitoring for recurrence, selecting treatments, and developing therapies.

On Tuesday, Guardant Health, Inc. announced that Palmetto GBA, a Medicare contractor responsible for the Molecular Diagnostics Services program (MolDX), has approved coverage for the Guardant Reveal test. This test is used to monitor patients with colorectal cancer (CRC) for any signs of disease recurrence after they have received treatment aimed at curing the disease.

On Tuesday, Guardant Health's stock reached its highest point in 13 months after Medicare decided to cover the company's blood test for colon cancer. This news contributed to the stock's significant rise, as reported by Investor's Business Daily.

Guardant Health, Inc. and ConcertAI have announced a partnership that enables biopharmaceutical companies to utilize a new type of multi-modal real-world data. This data combines detailed patient electronic medical records with genomic and epigenomic tumor profiling information. The collaboration aims to enhance precision oncology efforts.

Guardant Health (GH) experienced a significant rise in its stock price during the last trading session, with trading volume exceeding the usual amount. However, the recent changes in earnings estimates might not lead to additional price growth in the short term.

PALO ALTO, Calif. & TAMPA, Fla.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a top company in precision oncology, has teamed up with Meaningful Insights Biotech Analytics (MiBA), a forward-thinking healthcare tech firm. This partnership focuses on improving biomarker testing and data analysis to enhance precision medicine for patients within the MiBA Network. Acknowledging the changing field of precision medicine, the collaboration merges MiBA's advanced technology with Guardant Health's expertise.

COTA Inc., a top provider of real-world data and analytics for cancer research, has formed a partnership with Guardant Health Inc., a prominent precision oncology company. This collaboration will enable biopharmaceutical researchers to utilize COTA's high-quality electronic health record data alongside Guardant's genomic testing information, speeding up the creation of new cancer treatments. Together, they aim to enhance the resources available for cancer therapy development.